(Q33501473)

27 July 2017

title

Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis (English)

1 reference

27 July 2017

0 references

1 reference

1 reference

Furusyo N

1

1 reference

27 July 2017

Hayashi J

2

1 reference

27 July 2017

Ueno K

3

1 reference

27 July 2017

Sawayama Y

4

1 reference

27 July 2017

Kawakami Y

5

1 reference

27 July 2017

Kishihara Y

6

1 reference

27 July 2017

Kashiwagi S

7

1 reference

27 July 2017

publication date

1 November 1997

1 reference

27 July 2017

published in

Clinical Therapeutics

1 reference

27 July 2017

volume

19

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

1352-1367

1 reference

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Role of endogenous substance P in ethanol-induced mucosal damage in the rat stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Thrombocytopenia associated with hepatitis C viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980010-0

7 January 2021

10.1016/S0149-2918(97)80010-0

Identifiers

DOI

1 reference

release_v4foxagdgzghrn6qhsq6x4g4bq

27 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v4foxagdgzghrn6qhsq6x4g4bq

24 November 2022

mapped directly with Wikidata item

1 reference